Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

A Parathyroid Hormone Both Builds & Destroys Bone

Larry Beresford  |  Issue: March 2018  |  March 19, 2018

CLIPAREA l Custom media / SHUTTERSTOCK.COM

CLIPAREA l Custom media / SHUTTERSTOCK.COM

SAN DIEGO—A hormone secreted by the parathyroid gland is both a builder and a destroyer of bone in humans, with important implications for a variety of conditions treated by rheumatologists. In the Oscar Gluck, MD, Memorial Lecture at the 2017 ACR/ARHP Annual Meeting Nov. 3–8, Henry Kronenberg, MD, chief of the Endocrine Division at Massachusetts General Hospital and professor of medicine at Harvard Medical School, described the complex metabolic processes controlled by the parathyroid hormone (PTH).

Catabolic activity breaks down molecules for resorption and anabolic activity builds up or synthesizes complex molecules out of simpler ones. PTH is important in bone remodeling, the ongoing process in which bone tissue is alternately resorbed and rebuilt over time, and it is secreted in response to low blood serum calcium levels.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We think PTH exists primarily to increase calcium as the main calcium-regulatory peptide in the body,” Dr. Kronenberg said.

Blood calcium and PTH act promptly to regulate each other in the body. PTH also indirectly stimulates osteoclast cell activity within bone marrow, and increases the number and activity of osteoblasts by increasing the numbers of precursor cells to osteoblasts.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“It’s not an accident that bone formation and absorption are coupled,” Dr. Kronenberg said in his lecture. The proper maintenance of bone over time requires a balance between the formation of new bone tissue and the breakdown and removal (resorption) of old bone tissue.

The proper maintenance of bone over time requires a balance between the formation of new bone tissue & the breakdown & removal (resorption) of old bone tissue.

Dr. Kronenberg also outlined some of the medical conditions affected by these complex mechanisms, including bone disease in rheumatology or back injury, gluco­corticoid-induced osteoporosis and humoral hypercalcemia of malignancy.

Sclerosteosis, a mutation in the SOST gene, and Van Buchem disease, caused by a defect in genetic lesions, are examples of diseases that build bones to a harmful degree by suppressing sclerostin—a secreted glycoprotein encoded by the SOST gene in humans. Sclerostin’s main function is to inhibit bone formation. PTH acts to transiently suppress sclerostin synthesis and secretion by osteocytes; this is one of the ways that PTH increases bone formation.

Other health problems that result from too little or too much PTH (e.g., hypoparathyroidism, hyperparathyroidism and paraneoplastic syndromes) can wreak havoc in the form of bone disease, hypocalcemia and hypercalcemia.

Ultimately, Dr. Kronenberg said, PTH is a good banker, because the hormone causes bone to slowly store calcium, so the body can make withdrawals of calcium as needed to keep its appropriate level in the blood through ever-present challenges of metabolism, stress and nutritional variation. PTH is a key that unlocks the bank vault to remove the calcium and make sure the calcium is there when it’s needed.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsMeeting Reports Tagged with:ACR/ARHP Annual Meetingbone formation

Related Articles

    Build Up Bone

    June 1, 2007

    Current management of osteoporosis

    A Duet of Bone and the Immune System

    July 12, 2011

    Examining emerging perspectives in osteoimmunology

    New Treatments Needed to Prevent Fractures in Osteoporosis

    June 1, 2014

    Current therapies target pathways of bone remodeling, but rheumatologists say a better understanding of the mechanisms of bone resorption, formation is needed to make an impact

    Persistent Symptomatic Hypocalcemia Due to Denosumab: A Case Review

    October 1, 2014

    Patients with osteoporosis and impaired renal function are at risk

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences